MorphoSys AG ADR MOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MOR is a good fit for your portfolio.
News
-
Trending: Novartis Begins Tender Offer for MorphoSys Shares
-
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
-
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
-
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
-
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
-
Novartis to bolster its cancer-drug portfolio with $2.9 billion deal for MorphoSys
-
MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis
Trading Information
- Previous Close Price
- $18.04
- Day Range
- $17.91–18.08
- 52-Week Range
- $4.19–18.31
- Bid/Ask
- $18.00 / $18.03
- Market Cap
- $2.71 Bil
- Volume/Avg
- 17 / 2.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 524
- Website
- https://www.morphosys.com
Comparables
Valuation
|
Metric
|
MOR
|
HPHA
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 49.90 | 3.31 | 2.14 |
Price/Sales | 9.58 | 13.99 | 181.99 |
Price/Cash Flow | — | — | — |
Price/Earnings
MOR
HPHA
IGMS
Financial Strength
|
Metric
|
MOR
|
HPHA
|
IGMS
|
|---|---|---|---|
Quick Ratio | 3.14 | 2.31 | 7.95 |
Current Ratio | 3.57 | 2.86 | 8.18 |
Interest Coverage | — | −27.85 | — |
Quick Ratio
MOR
HPHA
IGMS
Profitability
|
Metric
|
MOR
|
HPHA
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −14.65% | −28.81% | −44.52% |
Return on Equity (Normalized) | −384.47% | −48.54% | −84.37% |
Return on Invested Capital (Normalized) | −41.44% | −38.60% | −77.23% |
Return on Assets
MOR
HPHA
IGMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hxxrmzntb | Yhtl | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pgzpcrj | Lkddyk | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pgsrtlyzk | Drbcbhc | $98.1 Bil | |
MRNA
| Moderna Inc | Tzvdvxh | Htbk | $39.1 Bil | |
ARGX
| argenx SE ADR | Hycymqnv | Nxrbh | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vtgrryf | Nbyls | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Njhjmbvhv | Cwwpcxm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kjyfzwcjt | Klbcn | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fhjzgxhszb | Qdmbdm | $12.5 Bil | |
INCY
| Incyte Corp | Jyckxssp | Nhjvrdr | $11.9 Bil |